Defining the risk of SARS-CoV-2 variants on immune protection
The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or …
COVID-19 vaccines: a review of the safety and efficacy of current clinical trials
Various strategies have been designed to contain the COVID-19 pandemic. Among them,
vaccine development is high on the agenda in spite of the unknown duration of the …
vaccine development is high on the agenda in spite of the unknown duration of the …
Immunogenicity of BA. 5 bivalent mRNA vaccine boosters
AY Collier, J Miller, NP Hachmann… - … England Journal of …, 2023 - Mass Medical Soc
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Skip to main content The New England Journal of Medicine homepage Advanced Search …
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …
CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques
Spike-specific neutralizing antibodies (NAbs) are generally considered key correlates of
vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[PDF][PDF] Background document on the Janssen Ad26. COV2. S (COVID-19) vaccine: background document to the WHO Interim recommendations for use of Ad26. COV2 …
World Health Organization - 2021 - apps.who.int
Background This background document was prepared by the Strategic Advisory Group of
Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines to inform the …
Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines to inform the …
Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine
Abstract The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …
coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in …
Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial
In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …
Immune correlates analysis of the ENSEMBLE single Ad26. COV2. S dose vaccine efficacy clinical trial
Measuring immune correlates of disease acquisition and protection in the context of a
clinical trial is a prerequisite for improved vaccine design. We analysed binding and …
clinical trial is a prerequisite for improved vaccine design. We analysed binding and …
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
A Chandrashekar, J Yu, K McMahan, C Jacob-Dolan… - Cell, 2022 - cell.com
The rapid spread of the SARS-CoV-2 Omicron (B. 1.1. 529) variant, including in highly
vaccinated populations, has raised important questions about the efficacy of current …
vaccinated populations, has raised important questions about the efficacy of current …